News
HROW
28.59
-2.67%
-0.79
Harrow Health: Strong Growth and Strategic Expansion Support Buy Rating; Price Target Unchanged at $63
TipRanks · 1d ago
Harrow Price Target Maintained With a $63.00/Share by BTIG
Dow Jones · 1d ago
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
Benzinga · 1d ago
Notable Tuesday Option Activity: HROW, CLOV, RCAT
NASDAQ · 2d ago
Harrow reports Q3 EPS 25c, consensus 30c
TipRanks · 2d ago
Harrow backs FY26 revenue view $350M-$365M, consensus $349.66M
TipRanks · 2d ago
Closing Bell Movers: Sanmina jumps over 20% on Q4 earnings beat
TipRanks · 2d ago
Harrow stock jumps as eye-care products deliver record Q3 sales
Seeking Alpha · 2d ago
Morning Movers: On Holding slips following quarterly results
TipRanks · 2d ago
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), Harrow Health (HROW)
TipRanks · 2d ago
AAON, Ziprecruiter, Rackspace Technology, Babcock & Wilcox And Other Big Stocks Moving Higher On Tuesday
Benzinga · 2d ago
Harrow Q3 2026 Earnings Call Transcript
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 2d ago
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say
NASDAQ · 3d ago
Harrow Shares Gain on 3Q Revenue Beat
Dow Jones · 3d ago
Harrow Health Reports Record Third-Quarter Revenue and Earnings
TipRanks · 3d ago
Harrow Health GAAP EPS of $0.25 beats by $0.06, revenue of $99.3M beats by $0.71M
Seeking Alpha · 3d ago
*Harrow 3Q Rev $99.3M >HROW
Dow Jones · 3d ago
*Harrow 3Q EPS 25c >HROW
Dow Jones · 3d ago
Harrow: Q3 Earnings Snapshot
Barchart · 3d ago
More
Webull provides a variety of real-time HROW stock news. You can receive the latest news about Harrow Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.